Claudia TschabuschnigHome99% wasn't enough: How persistence in imaging changes the pictureTwo patient stories told at the European Parliament proved that a second look can change everything.July 6, 2026CTImaging takes center stage in Europe's Safe Hearts PlanRadiology and nuclear medicine are poised to play a central role in implementing the European Commission's Safe Hearts Plan, speakers said during a joint ESR/EANM event in Brussels.July 2, 2026Editor's NoteAuntMinnieEurope.com CT InsiderThis Insider tracks the muscle hiding in plain sight on coronary CT, the guesswork still baked into contrast agent safety, and Germany's screening rollout hitting real-world friction.July 1, 2026CTCan side-chain chemistry help radiologists choose a safer contrast agent after a hypersensitivity reaction?Choosing an alternative contrast agent after an allergic reaction often falls to clinical judgment. A new review examines whether side-chain chemistry can make that decision a little more evidence based.July 1, 2026AIMore work than relief: AI in the wrong seat, RCR census findsAI adoption is climbing fast across U.K. radiology and cancer services, but put in the wrong room, it creates more noise than signal.June 29, 2026Organized Radiology IssuesU.K. radiologist staffing lags EU peers, RCR census showsA growing shortage of radiologists, surging imaging demand, and mounting reliance on costly temporary staffing are placing increasing pressure on U.K. imaging services, according to the Royal College of Radiologists' latest workforce census.June 25, 2026Editor's NoteAuntMinnieEurope Molecular Imaging InsiderTheranostics is moving to clinical practice and questions on infrastructure get louder.June 24, 2026Molecular ImagingPET RANO gains visibility as neurotheranostics research advancesStandardized PET response assessment, emerging theranostic targets, and new strategies to overcome the blood-brain barrier are among the developments shaping neuro-oncology research.June 24, 2026Molecular ImagingAs theranostics advances, access challenges remain across EuropeTheranostics is advancing rapidly, but access remains uneven across Europe. According to Prof. Clemens Decristoforo, differences in national regulations and healthcare systems continue to influence patient access to innovative radiopharmaceuticals.June 24, 2026Molecular ImagingSix European societies launch RLT Referral Pathways ProjectRadioligand therapy has proven itself clinically for advanced prostate cancer. What hasn't caught up is Europe's healthcare infrastructure.June 23, 2026Page 1 of 11Next PageTop StoriesHome99% wasn't enough: How persistence in imaging changes the pictureTwo patient stories told at the European Parliament proved that a second look can change everything.Molecular ImagingPET/MRI can reduce the need for biopsies in prostate cancerCTImaging takes center stage in Europe's Safe Hearts PlanCTCan side-chain chemistry help radiologists choose a safer contrast agent after a hypersensitivity reaction?AIMost patients want to know if AI being used for imaging reports
